Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard LITTLETON, Colo., October 21, 2026 — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company
- Exchange
- The Nasdaq Stock Market LLC
- Kind
- regained compliance
- Rule
- Listing Rule 5550(b)(1)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The letter removes a delisting threat, which could stabilize or slightly lift the share price.
Market read
Primary relevance is to VVOS shareholders; limited broader market effect.
What to watch
Potential dilution from conversion of the Series C preferred could offset equity gains if cap is lifted.
Background
The filing is a standard 8‑K Item 8.01 disclosure of a Nasdaq compliance letter after a recent equity transaction.
Ticker impact
Vivos Therapeutics disclosed receipt of a Nasdaq compliance letter confirming it meets the $2.5M stockholders' equity requirement, removing immediate delisting risk.
likely modest upside as investors price in reduced delisting risk
The filing is the first public confirmation of compliance; no new financing or earnings data, but the risk of delisting is eliminated.
Market effects
Minimal; confirms compliance for a niche medical‑device firm, no broader sector impact.
None
Low
Counterpoint
If the equity boost from the preferred stock issuance is over‑estimated, the compliance may be temporary.
Key entities
- companyVivos Therapeutics, Inc.
Medical device and healthcare services company focused on obstructive sleep apnea.
- exchangeNasdaq Stock Market LLC
Issuer of the compliance letter confirming listing rule adherence.

